News Releases
Apr 02, 2019
Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy
Additional Formats
Apr 02, 2019
Sangamo Announces Agreement Securing Access To Large-Scale, Commercial-Grade Manufacturing Capacity At Brammer Bio
Additional Formats
Apr 01, 2019
Sangamo Therapeutics To Host April 2, 2019 Conference Call To Provide Clinical Update
Additional Formats
Mar 29, 2019
Sangamo Therapeutics Presents New Preclinical Data Demonstrating Significant Reduction In Tau Expression With Gene Regulation Technology
Additional Formats
Mar 12, 2019
Sangamo Therapeutics Appoints Jason Fontenot, Ph.D., As Senior Vice President, Cell Therapy
Additional Formats
Mar 08, 2019
Sangamo Therapeutics Announces Publication Of Data Demonstrating New Zinc Finger Nuclease Architectures Enabling High-Precision Genome Editing
Additional Formats
Mar 06, 2019
Sangamo Therapeutics Announces Participation At Upcoming Investor Conferences
Additional Formats
Feb 28, 2019
Sangamo Therapeutics Reports Fourth Quarter And Full Year 2018 Financial Results
Additional Formats
Feb 21, 2019
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2018 Conference Call and Webcast
Additional Formats
Feb 20, 2019
Sangamo Announces FDA Acceptance of IND Application for ST-920 Gene Therapy Candidate for Fabry Disease
Additional Formats
Displaying 11 - 20 of 26